STOCK TITAN

Maravai LifeSciences Holdings, Inc. - MRVI STOCK NEWS

Welcome to our dedicated page for Maravai LifeSciences Holdings news (Ticker: MRVI), a resource for investors and traders seeking the latest updates and insights on Maravai LifeSciences Holdings stock.

Maravai LifeSciences Holdings, Inc. (symbol: MRVI) is a leading life sciences company dedicated to advancing human health by providing specialized products and services to support the development of drug therapies, diagnostics, and novel vaccines. Formed in March 2014 through a partnership with GTCR, a private equity firm, Maravai LifeSciences has built a portfolio of successful, entrepreneurial life science companies.

Maravai’s portfolio companies are spearheading innovations in life sciences research and bioproduction, offering enabling tools and services that facilitate breakthroughs in genomics, proteomics, and biotherapeutic development. The company’s core business includes two primary segments: Nucleic Acid Production and Biologics Safety Testing. A significant portion of Maravai's revenue is generated from Nucleic Acid Production, which involves the manufacturing and sale of nucleic acid products essential for research and the development of vaccines and therapies.

Maravai LifeSciences has acquired four market-leading companies to date, enhancing its portfolio of products and services. Notably, Vector Laboratories is recognized for its labeling and detection products used in immunohistochemistry and immunofluorescence. Another key entity, TriLink BioTechnologies, continues to advance the field with its innovative solutions.

Recent achievements and ongoing projects underscore Maravai’s commitment to growth and innovation. The company remains focused on expanding its product portfolio, maintaining market leadership, and driving scientific advancements. The latest financial results highlight Maravai's robust performance, with continued revenue growth and strategic investments in new areas of research and development.

Maravai LifeSciences is actively engaged in discussions and presentations at prominent investor forums, such as the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum and the RBC Healthcare Conference, showcasing its leadership and strategic direction. These events provide valuable insights into Maravai’s ongoing initiatives and future outlook.

For more detailed information about Maravai LifeSciences, including recent news and updates, visit the Maravai LifeSciences website.

Rhea-AI Summary
TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), secures global patents for its CleanCap® Capping Technology, enhancing the production of synthetic mRNA for innovative medicines. The patents from China and Canada strengthen TriLink's intellectual property protection, complementing existing patents in major markets. CleanCap® technology has been pivotal in developing COVID-19 vaccines and promises faster drug commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none
-
Rhea-AI Summary
Maravai LifeSciences, Inc. (MRVI) will announce its Q4 and full year 2023 financial and operating results on February 22, 2024. The company is a global provider of life science reagents and services to researchers and biotech innovators. A conference call and webcast will be hosted on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
conferences earnings
-
Rhea-AI Summary
Maravai LifeSciences, Inc. (NASDAQ: MRVI) to participate in investor conferences in November 2023. CEO and CFO to join fireside chats at Stifel Healthcare Conference and Jefferies London Healthcare Conference. Webcasts available on Maravai's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Maravai LifeSciences Holdings, Inc. (MRVI) Announces Realignment to Drive Operational Efficiencies and Streamline the Business Post-Pandemic with $66.9 million Quarterly Revenue and a 15% Workforce Reduction
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.69%
Tags
-
Rhea-AI Summary
TriLink BioTechnologies, a Maravai LifeSciences company, has launched its Analytical Sciences Center of Excellence (ASCE) hub in San Diego. The 4,000-square-foot lab will serve as the centralized hub for advanced testing of nucleic acids, minimizing delays and costs associated with outsourced testing. The center of excellence will expand analytical capabilities, develop new methodologies, and improve NMR, NGS, and LNP characterization. TriLink is a leader in mRNA specific analytical services and has developed 10 unique methods for mRNA characterization. The ASCE will support developers in advancing their drugs, starting with plasmid DNA and continuing through mRNA manufacturing and release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
Rhea-AI Summary
Maravai LifeSciences to announce Q3 2023 financial results and host conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
conferences earnings
Rhea-AI Summary
Maravai LifeSciences Holdings, Inc. hosted its 2023 Investor R&D Day, highlighting its strong foundation for growth and attractive long-term outlook. The company aims for high teens revenue growth and expanding EBITDA margins. Maravai focuses on customer success and holds more than 120 patents. They are targeting $700M in revenue and >40% adjusted EBITDA in 2028. They have a comprehensive growth strategy and a strong financial position for future acquisitions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
-
Rhea-AI Summary
Maravai LifeSciences' Chief Innovation Officer, Dr. Kate Broderick, has been named to the 2023 PharmaVoice 100 list, recognizing inspiring leaders in the life sciences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
-
Rhea-AI Summary
Maravai LifeSciences Holdings, Inc. to host 2023 Investor R&D Day on September 28, featuring presentations by CEO and senior leadership team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.53%
Tags
conferences
Rhea-AI Summary
Cygnus Technologies, part of Maravai LifeSciences, received a 2023 R&D 100 Award for the MockV® RVLP Kit, enabling bioprocess scientists to determine RVLP removal during biopharmaceutical manufacturing. The kit offers a cost-effective alternative to traditional viral clearance studies, saving time and money. This innovative technology improves biopharmaceutical manufacturing safety and allows companies to develop processes for safe biotherapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none

FAQ

What is the current stock price of Maravai LifeSciences Holdings (MRVI)?

The current stock price of Maravai LifeSciences Holdings (MRVI) is $5.37 as of December 20, 2024.

What is the market cap of Maravai LifeSciences Holdings (MRVI)?

The market cap of Maravai LifeSciences Holdings (MRVI) is approximately 776.6M.

What does Maravai LifeSciences Holdings, Inc. specialize in?

Maravai LifeSciences specializes in providing products and services that support the development of drug therapies, diagnostics, and novel vaccines, as well as research in genomics, proteomics, and biotherapeutic development.

When was Maravai LifeSciences formed?

Maravai LifeSciences was formed in March 2014 through a partnership with GTCR, a leading private equity firm.

What are the main business segments of Maravai LifeSciences?

The main business segments of Maravai LifeSciences are Nucleic Acid Production and Biologics Safety Testing.

Which companies are part of Maravai LifeSciences' portfolio?

Maravai LifeSciences' portfolio includes Vector Laboratories and TriLink BioTechnologies, among others.

Where can I find the latest financial results of Maravai LifeSciences?

The latest financial results of Maravai LifeSciences can be found on their investor relations website, under News & Events.

How does Maravai LifeSciences support scientific research?

Maravai LifeSciences supports scientific research by providing essential tools and services for genomics, proteomics, and biotherapeutic development.

What recent events has Maravai LifeSciences participated in?

Maravai LifeSciences has participated in events such as the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum and the RBC Healthcare Conference.

How can I access Maravai LifeSciences' presentations at investor forums?

Presentations from investor forums can be accessed via live webcasts on the Maravai LifeSciences Investor Relations website, with archived versions available post-event.

What is the mission of Maravai LifeSciences?

The mission of Maravai LifeSciences is to build a transformative life sciences reagents company by acquiring outstanding businesses and accelerating their growth.

Where can I find more information about Maravai LifeSciences?

More information about Maravai LifeSciences can be found on their official website at www.maravai.com.

Maravai LifeSciences Holdings, Inc.

Nasdaq:MRVI

MRVI Rankings

MRVI Stock Data

776.59M
119.61M
1.37%
102.83%
4.91%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO